Compare DexCom, Inc. (DXCM) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MasterCard Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while MasterCard Inc trades at $574.4 (market cap $499.38B). The key difference: MasterCard Inc is far larger — about 15.7× DexCom, Inc.'s market cap, and MasterCard Inc pays a 0.61% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and MasterCard Inc for 134 Days on average.
| DXCM | MA | |
|---|---|---|
Market Cap | $31.81B | $499.38B |
Volume | 2,861,821 | 1,862,680 |
Sector | Health | Financials |
52-Week High | $92.34 | $599.86 |
52-Week Low | $54.84 | $471.55 |
Typical Hold Time | 62 Days | 134 Days |
Enterprise Value | $31.26B | $512.41B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Mastercard (MA) trades at $570.06, up 0.61% with a bullish technical signal and strong institutional interest. The company demonstrates robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining exceptional profitability margins. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $5.04 surpassing the $4.77 estimate. Analyst consensus remains strongly positive with 80% buy ratings and a $666.67 price target, representing 17% upside potential from current levels.
Mastercard presents a compelling growth opportunity with expanding digital payments adoption and strong execution, though faces risks from payment industry disruption and competitive threats. The stock's premium valuation (P/E 31.36) reflects high growth expectations that must be sustained. Near-term catalysts include Q3 2026 earnings and continued AI payment innovation, while regulatory scrutiny and economic sensitivity remain key monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
